Drug
Glycopyrrolate
Glycopyrrolate: highest development phase Phase 2, developed by Chiesi Farmaceutici, Merck. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Chiesi Farmaceutici, Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Glycopyrrolate (85 μg) NCT06545500 | Phase 2 | Chronic Obstructive Pulmonary Disease |
| Glycopyrrolate NCT01476813 | Phase 2 | Pulmonary Disease, Chronic Obstructive |
Latest
No recent events.
Follow Glycopyrrolate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.